E. Chan

Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1

A. Jakubowiak, S. Trudel, M. Tomasson, 2021, Blood.

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

A. Jakubowiak, S. Trudel, M. Tomasson, 2022, Blood.

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial

A. Jakubowiak, S. Trudel, M. Tomasson, 2023, Nature Medicine.